Biohaven drops as US FDA seeks more BHV-7000 safety data
BHVN•FDA seeks more BHV-7000 safety data
- Shares of drugmaker Biohaven (BHVN.N) fell 19.6% to $12.1 in premarket trading.
- The company's BHV-7000 program was partially placed on clinical hold after the FDA sought more information about a potential safety issue seen in animal studies.
- The pause affects only new patient enrollment, while more than 600 patients already enrolled in the study can continue receiving treatment, the company said.
- BHV7000-303 remains on track to report topline data in the second half of 2026.
- If losses hold, BHVN is set to open at its lowest level since mid-June.
- Twelve of 17 brokerages rate the stock "buy" or higher, four "hold" and one "sell"; their median price target is $20, according to data compiled by LSEG.
- As of the last close, BHVN stock was up 32.9% year to date.
Related News
Houthis seize key Yemeni Red Sea port, sources say, threatening global energy flows
XLE•
Hormuz shipping traffic in single digits, data shows
XLE•
